Sophia Genetics raised $110 million in a Series F round led by aMoon

Sophia Genetics, a Lausanne, Switzerland and Boston, USA-based Data-Driven Medicine provider, announced that it closed an oversubscribed Series F round exceeding $110 million.

The round was led by major health-tech fund aMoon, a leading health-tech & life sciences venture fund based in Israel, and Hitachi Ventures, a venture arm of Japanese Hitachi Group. Didier Hirsch, former CFO at Agilent, joins the company’s Board of Directors and will chair its Audit Committee.

The company also was backed by the financial institutions Credit Suisse and the Pictet group. Existing investors Swisscom Ventures, Endeavour Vision, Generation Investment Management, Alychlo, and Eurazeo Growth participated in the round, as well as newcomers ACE & Company and Famille C Invest.

Sophia Genetics, founded in 2011 by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz as a start-up at École Polytechnique Fédérale de Lausanne, established the world’s largest Data-Driven Medicine community network through its universal and collaborative AI platform. The company supports healthcare professionals by translating multiple sources of complex medical data into valuable clinical insights.

The SOPHiA Platform is used by over 1000 healthcare institutions and has analyzed 600k genomic profiles; up to 17000 new profiles a month. Through continual learning and network effects, experts worldwide are empowered to act with confidence for better patient management.